Copy Product Info
Catalog No. TP2252 Cas No. 161748-29-4
GLP-1 (9-36) amide is an antagonist at the human GLP-1 receptor. GLP-1 (9-36) amide potently inhibits hepatic glucose production (HGP) and is a weak insulinotropic agent.
Catalog No. TP2252
Cas No. 161748-29-4
Add to Cart
Add to Quotation
In Stock Estimated shipping date USA Warehouse 1-2 days Global Warehouse 5-7 days
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Q What’s Ki?
A Inhibitory consent (Ki) reflects the strength of inhibitor binding to the target, corresponding to the concentration of free inhibitor when 50% of the target is bound by the inhibitor.
Q What’s pIC50?
A pIC50 is the negative log of the IC50 value when converted to molar.That is, pIC50=-log(IC50).
Q What’s Kd?
A Dissociation consent (Kd) reflects the affinity of a compound for its target. In some cases, it can be equivalent to Ki.
Q Does the compound differ in any way when it is in the form of hydrochloride or sulfate ions? What is the difference between the salt form and the free form?
A The molecules in salt and non-salt forms exhibit the same activity, and they have consistent effects in biological experiments. Their activity and usage are identical. The only difference lies in their salt forms, which may result in variations in physical properties such as solubility. It is recommended to choose based on solubility and experimental requirements.
Q What’s EC50?
A Half maximal effective concentratioin(EC50) refers to the concentration of a compound that achieves 50% of the maximum effect(inhibitory/stimulatory effect),after a specified exposure duration.
Purity: 97%
Appearance: Solid
Color: White
Contact us for more batch information
Description GLP-1 (9-36) amide is an antagonist at the human GLP-1 receptor. GLP-1 (9-36) amide potently inhibits hepatic glucose production (HGP) and is a weak insulinotropic agent. In vivo After subcutaneous (s.c.) administration of GLP-1 to dogs the plasma immunoreactivity of GLP-1 measured by two different radioimmunoassays (RIAs) were higher than that measured by a sandwich enzyme-linked immunosorbent assay (ELISA). This discrepancy was due to the formation of the metabolites GLP-1-(9-36) amide, GLP-1-(7-35) and GLP-1-(7-34). Receptor binding studies using baby hamster kidney cells expressing the human pancreatic GLP-1 receptor showed that the affinity of GLP-1-(9-36) amide was 0.95% of the affinity of GLP-1-(7-36) amide. Furthermore, GLP-1-(9-36) amide was shown to be an antagonist to adenylyl cyclase activity. GLP-1-(9-36) amide was shown to be present in vivo in amounts up to 10-fold that of GLP-1-(7-36) amide.
Molecular Weight 3089.41
Formula C 140 H 214 N 36 O 43
Smiles CC[C@H](C)[C@@H](C(N[C@@H](C)C(N[C@@H](Cc1c[nH]c2c1cccc2)C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCNC(N)=N)C(N)=O)=O)=O)=O)=O)=O)=O)NC([C@H](Cc1ccccc1)NC([C@H](CCC(O)=O)NC([C@H](CCCCN)NC([C@H](C)NC([C@H](C)NC([C@H](CCC(N)=O)NC(CNC([C@H](CCC(O)=O)NC([C@H](CC(C)C)NC([C@H](Cc(cc1)ccc1O)NC([C@H](CO)NC([C@H](CO)NC([C@H](C(C)C)NC([C@H](CC(O)=O)NC([C@H](CO)NC([C@H]([C@@H](C)O)NC([C@H](Cc1ccccc1)NC([C@H]([C@@H](C)O)NC(CNC([C@H](CCC(O)=O)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O
Relative Density. 1.46 g/cm3 (Predicted)
Sequence Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Lys-Gly-Arg
Sequence Short EGTFTSDVSSYLEGQAAKEFIAWLVKGR
Storage store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information 0.025% acetic acid: 2 mg/mL (0.65 mM), Sonication is recommended.
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method: For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH 2 O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline, PBS or ddH 2 O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Related Tags: buy GLP-1 (9-36) amide | purchase GLP-1 (9-36) amide | GLP-1 (9-36) amide cost | order GLP-1 (9-36) amide | GLP-1 (9-36) amide chemical structure | GLP-1 (9-36) amide in vivo | GLP-1 (9-36) amide formula | GLP-1 (9-36) amide molecular weight
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, improve your experience, and analyze site usage.
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.
